Drugs-Forum  
Home Wiki Studies Forum Groups Blog Video Images News
Go Back   Drugs Forum > Wiki Articles > Drug Articles
Mark Forums Read
Register Tags

Notices

Drug Articles Articles about drugs

5-IAI

5-IAI is a rigid analogue of amphetamine that has been demonstrated to behaviorally substitute for MDMA, and acts as a monoamine releasing agent. The compound has been suggested to present similar serotonergic neurotoxicity, though considerably lower in severity, to MDMA

Contents




[top]Introduction to 5-IAI


5-IAI (5-Iodo-2-aminoindane) is a rigid analogue of amphetamine that has been demonstrated to behaviorally substitute for MDMA, and acts as a monoamine releasing agent. The compound has been suggested to present similar serotonergic neurotoxicity, though considerably lower in severity, to MDMA[1].


[top]Using 5-IAI


[top]Ways of administration


[top]Effects


[top]Combinations with 5-IAI


[top]Different Uses




[top]Pharmacology

5-IAI behaves as a non-vesicular releasing agent for serotonin, dopamine, and norepinephrine - observed to potently inhibit the uptake of monoamines into reserpinized synaptosomes. The compound appears to have lower serotonergic, dopaminergic, and noradrenergic activity than MDMA, MDA, and MDAI (among others) - as the table below demonstrates.

[1]

Non-vesicular monoamine releasers have been observed to act as uptake inhibitors in typical uptake inhibition experiments, and it has been shown that if a drug is a releaser of non-vesicular monoamines - in contrast with 'pure' uptake inhibitors - it will appear to be more potent in reserpinized synaptosomes than in control animals' synaptosomes. 5-IAI is more potent in reserpinized synaptosomes than control for both serotonin and dopamine, and this method cannot characterize norepinephrine releasing activity[1].


[top]Chemistry of 5-IAI



[top]The dangers of 5-IAI

While 5-IAI has been suggested to generate some serotonergic neurotoxicity, it's been posited that such activity is not as significant as related compounds. However, Nichols et. al. are careful to state that the data derived from the above study cannot contribute to a simple relationship between serotonergic neurotoxicity for several reasons. First, the reserpinized synaptosome method used is incapable of distinguishing uptake inhibition from release of non-vesicular norepinephrine - and despite the fact that 5-IAI was observed to inhibit norepinephrine uptake, there is no obvious trend characterizing either neurotoxic or non-neurotoxic compounds to be more potent noradrenergic uptake inhibitors. A similar concern exists for serotonin, as all drugs tested were potent non-vesicular serotonin releasers - including both neurotoxic and non-neurotoxic agents. Finally, in vivo pharmacokinetic factors have not been established for 5-IAI - and evidence exists suggesting that the drugs vary widely regarding such properties; for example, 5-IAI and PIA are characterized by considerably lower potency in substituting for MDMA in drug discrimination experiments than would be anticipated from the in vitro data presented in the tables provided by the study. Accordingly, 5-IAI cannot be definitively characterized as a non-neurotoxic substitute for MDMA, despite evidence supporting lower levels of serotonergic neurotoxicity[1].

[1]

The following figure demonstrates the apparently low level of serotonergic neurotoxicity. PIA caused a significant decrease in serotonergic markers a week after a single 40mg/kg dose - and 5-IAI appeared to be significantly less neurotoxic, as only a slight decrease of serotonergic markers (15% or less) was observed a week subsequent to one 40 mg/kg SC dose. The only statistically significant decreases were observed in cortical uptake sites, as well as hippocampal levels of serotonin. Importantly, 40 mg/kg SC is 20- to 40- times higher than required for behavioral activity - and comparable doses of many amphetamine analogues has been observed to approach fatal levels[2].



Hospitalization from 5-IAI


[top]Production




[top]Forms of 5-IAI




[top]Legal status of 5-IAI

[top]United Nations

[top]USA

[top]EU

[top]Other Countries



[top]History

[top]Popularity of over time





[top]The latest 5-IAI threads

  Article / Page Starter Last Post Comments Views
electricvelvet
23-04-2014 05:45
by monkeyking Go to last post
5 310
Hollowbin
21-04-2014 19:05
by Hollowbin Go to last post
2 102
Missedflop
21-04-2014 01:40
by Thepsychonaut Go to last post
28 3,278
mandy23
18-04-2014 05:17
by Lady Codone Go to last post
5 617
davestate
17-04-2014 15:21
by Raskolnikov Go to last post
177 127,008
uncle_bud
17-04-2014 14:00
by dr ACE Go to last post
3 189
fro5529
17-04-2014 10:06
by benzopiated Go to last post
3 373
Joel2k11
13-04-2014 04:10
by MenTal_PaTienT Go to last post
3 3,054
psychedelaholic
08-04-2014 23:54
by (NS)-M-Lo-Reason Go to last post
7 12,140
bigsleep
06-04-2014 09:04
by bigsleep Go to last post
0 144


[top]References

  1. ^ a b c d e Johnson, Michael, Conarty, Paul, Nichols, David [3H]Monoamine releasing and uptaking inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues
  2. ^ Nichols, David, Johnson, Michael, Oberlender, Robert, 5-Iodo-2-Aminoindan, a Nonneurotoxic Analogue of p-Iodoamphetamine


Attached Images
File Type: gif 5-iai.gif (5.5 KB, 1312 views)
Created by Gradient, 13-08-2010 at 03:11
Last edited by NeuroChi , 22-02-2011 at 02:16
Last comment by Gradient on 22-07-2011 at 00:45
3 Comments, 31,243 Views

Share this on:

Tags
5-iai, 5-iodo-2-aminoindane, 5-iodoaminoindane, aminoindanes, wiki, wiki writers
Page Tools


Posting Rules
You may not create new articles
You may not edit articles
You may not protect articles

You may not post comments
You may not post attachments
You may not edit your comments

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Sitelinks: Information:

All times are GMT +1. The time now is 14:43.


Copyright: SIN Foundation 2003 - 2014, All rights reserved
"Wiki" powered by VaultWiki v3.0.20 PL 1.